Study title:
Friebel-D, von-der-Hagen-M, Baumgartner-E-R, Fowler-B, Hahn-G, Feyh-P, Heubner-G, Baumgartner-M-R, Hoffmann-G-F.
Department of Neuropaediatrics, Children's Hospital, Technical University of Dresden, Dresden, Germany.
The first case of 3-methylcrotonyl-CoA carboxylase (MCC) deficiency responsive to biotin.
Neuropediatrics, {Neuropediatrics}, Apr 2006, vol. 37, no. 2, p. 72-8, ISSN: 0174-304X.Friebel-D, von-der-Hagen-M, Baumgartner-E-R, Fowler-B, Hahn-G, Feyh-P, Heubner-G, Baumgartner-M-R, Hoffmann-G-F.
Department of Neuropaediatrics, Children's Hospital, Technical University of Dresden, Dresden, Germany.
The first case of 3-methylcrotonyl-CoA carboxylase (MCC) deficiency responsive to biotin.
Neuropediatrics, {Neuropediatrics}, Apr 2006, vol. 37, no. 2, p. 72-8, ISSN: 0174-304X.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Nutritional and Metabolic Diseases [C18]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: BIOTIN |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|